Skip to content
Posters & Publications
- Kaplan, In Vitro Characterization of API-1252, a Novel Inhibitor of Bacterial Fatty Acid Biosynthesis, Against Drug Resistant Staphylococci, 2006 [ 66 KB]
- Zhanel, Activity of API-1252, a Novel Fabl Inhibitor, Against Healtcare-Associated and Community-Associated Methicillin-Resistant Staphylococcus aureus from Canadian Intensive Care Units, 2006 [ 198 KB]
- Zhanel, Activity of AFN-1252, a Novel Fabl Inhibitor, Against Methicillin-Susceptible and Methicillin-Resistant Staphylococcus epidermidis from Canadian Intensive Care Units, 2007 [ 93 KB]
- Perdreau-Remington, Activity of the Novel Anti-Staphylococcal Agent AFN-1252 against Genotypically Unique Strains of Staphylococcus aureus, 2007 [ 195 KB]
- Karlowsky, AFN-1252, a FabI Inhibitor, Demonstrates a Staphylococcus-Specific Spectrum of Activity, 2009 [ 59 KB]
- Kaplan, Specific Anti-Staphylococcal Activity of AFN-1252, a Novel Fatty Acid Synthesis Inhibitor, 2009 [ 250 KB]
- Banevicius, In Vivo Pharmacodynamic Profiling of API-1252 Against Staphylococcus aureus in a Murine Thigh Model, 2006 [ 157 KB]
- Banevicius, Comparative Dose Studies of AFN-1252 and Linezolid Against Methicillin-Resistant and Susceptible Staphylococcus aureus in a Murine Pneumonia Model, 2007 [ 120 KB]
- Weiss, Efficacy of AFN-1252 and Vancomycin in the Mouse Subcutaneous Abscess Model with a Methicillin-Resistant S. aureus, 2008 [ 95 KB]
Duo an num quam fuisset sadipscing, elit animal doc endi enum num ut.
